Report type: Weekly Strategy
Major Market Trends That Are Appearing
With the MC being decided for the Kohaku Uta Gassen that takes place on New Year’s Eve, it is now the period where there is a focus on the year-end and New Year holidays. With the implementation of the consumption tax hike from this month, although it should be the time where there is a growing public opinion of “whether there will be a factor for the Japanese economy to improve after the 2020 Tokyo Olympics”, it seems to indicate that major market trends towards next year will be related to countermeasures for climate change risks and semiconductor-related stocks.
In the Japanese stock market in the week of 15/10, while news of the growing scale of damages due to Typhoon Hagibis unfolded, such as banks being breached, there were also increased expectations towards a supplementary budget such as from Prime Minister Abe’s answer in the Diet, “With unprecedented disasters happening one after another, our past experiences and preparations alone will no longer suffice. As a country, we will make strong efforts towards National Resilience, and with this far-sighted policy, we shall build a nation which does not succumb to disasters”, which led to a purchasing trend focusing on the construction and civil engineering-related. Also, for the Nikkei average, after exceeding 22,000 points and approaching it on 15/10, on 16/10 it exceeded 22,500 points at once, which was a sudden rise in the stock market that renewed the year’s high. The reason for this is believed to be due to the following: at 11/10, there was a large difference in amount when comparing 1.598 trillion yen of the unresolved arbitrage of the “unsettled selling balance of arbitrage” at the “long futures position / short spot position”, and 478.2 billion yen of the “unsettled buying balance of arbitrage” (unresolved arbitrage involving the unsettled balance of spot purchases at the “short futures position / long spot position”), and this resulted in a buyback of spot trading stocks to cancel arbitrage, which therefore also greatly influenced the supply and demand factors that cause the market to rise.
As a countermeasure for the heat, it was decided that the Tokyo Olympics marathon would be held at Sapporo. It was also reported that fire ants originating from South America carrying powerful venom had possibly colonised at Aomi Container Terminal. In addition, news involving abnormal weather have been on the rise, such as consecutive poor catches of pacific saury, which is a characteristic flavour of fall dishes. At the same time on 30/9, a Goldman Sachs report was published which involved repercussions of climate change on cities all over the world, and in terms of flood risks, it warned that a part of Tokyo would also face the danger of being submerged into the ocean. It is predicted that awareness of climate change risks will grow even stronger, which may serve as an opportunity for companies who contribute to the safety of people’s lives and lifestyles to reassess their value. Also, in the 3Q (Jul-Sep) results of FY2019/12 for overseas companies, 5G or IoT compatibility, such as in semiconductor equipment manufacturers, etc., the miniaturization of semiconductors which contribute to increased performance in smartphones, and the rise in demand for logic semiconductors, etc. have been confirmed, which point to an increasing chance of business performance bottoming out. Those related to semiconductors are also expected to drive the market.
In the 21/10 issue, we will be covering Doutor Nichires Holdings (3087), Sumitomo Dainippon Pharma (4506), Shionogi (4507), Takaoka Toko (6617), Net One Systems (7518) and Toho (9602).
・Established in 2007 as a holding company following a business merger between Nippon Restaurant System and Doutor Coffee. Their mainstay business involves the management of F&B restaurants in various lines of business as well as the roast processing and retail of coffee. Expands brands such as “Doutor Coffee Shop”, “Excelsior Caffé”, in addition to “Hoshino Coffee” and “Yomenya Goemon”, etc.
・For 1H (Mar-Aug) results of FY2020/2 announced on 15/10, net sales increased by 1.1% to 66.908 billion yen compared to the same period the previous year, operating income increased by 7.1% to 6.247 billion yen, and net income increased by 3.3% to 3.874 billion yen. Company is focusing on introducing new products in Doutor Coffee Shop and Excelsior Caffé. Fine tuning of existing business categories such as Yomenya Goemon, etc. have also contributed.
・For its full year plan, net sales is expected to increase by 3.2% to 133.315 billion yen compared to the previous year, operating income to increase by 5.7% to 10.721 billion yen, and net income to increase by 9.9% to 6.503 billion yen. The content that was announced on 12/4 remain unchanged. At the same time, a dividend increase was also announced. Annual dividend forecast has been raised from 32.00 yen to 34.00 yen. Company’s policy is to reinforce product appeal and the launch of new outlets.
・Its predecessor was Osaka Pharmaceutical which was established in 1897. Merged with Sumitomo Pharmaceuticals in Oct 2005, and Sumitomo Chemical (4005) became their parent company with an ownership of 51.6%. Sales revenue distribution ratio for North America exceeds 50%. Emphasises on antipsychosis, anti-cancer and cell regeneration.
・For 1Q (Apr-Jun) results of FY2020/3 announced on 29/7, sales revenue increased by 1.4% to 117.484 billion yen compared to the same period the previous year, and core operating income which excludes non-ordinary items from the operating income increased by 20.9% to 22.275 billion yen. Despite core segment profits in Japan decreasing by 23.0%, the 18.0% increase in their mainstay North America and 63.8% increase in China and overseas businesses have contributed.
・For its full year plan, sales revenue is expected to increase by 3.4% to 475 billion yen compared to the previous year, and core operating income to decrease by 0.4% to 77 billion yen. It was announced on 26/9 that the teams, such as the Tokyo Dental and Medical University, succeeded in creating the world’s first “mini multi-organ” connecting the liver and pancreas from human iPS cells. The company is strong in mass production technology of iPS cells and is proactively developing regenerative cell medicine, and we can look forward to the results from their mid and long-term stance.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
